Medtronic had a strong 2025 despite challenges like tariffs. In 2026, it’s still a good investment for long-term income seekers. The company plans to separate its diabetes division, which has lower operating margins, to focus on B2B operations. Medtronic’s Hugo system for robotic-assisted surgery opens new growth opportunities in an underpenetrated market.

The Hugo system won’t boost revenue immediately, but it sets Medtronic up for long-term success. The company’s dividend history and growth potential make it an attractive investment. Despite missing The Motley Fool’s top 10 stocks list, Medtronic remains a strong choice for investors seeking steady returns.

Read more at Yahoo Finance: 3 Reasons to Add This Medical Technology Stock to Your Portfolio in 2026